A5083894109- Pharmaceutical studies and practices
- Vascular Malformations and Hemangiomas
- Vascular Anomalies and Treatments
- Inflammatory Bowel Disease
- Celiac Disease Research and Management
- Research on Leishmaniasis Studies
- Microscopic Colitis
- Tracheal and airway disorders
- Psoriasis: Treatment and Pathogenesis
Hospital Universitario Infanta Leonor
2020
Hospital Universitario Fundación Alcorcón
2019
Objectives Epistaxis is the most frequent clinical manifestation of hereditary hemorrhagic telangiectasia (HHT). Several topical, systemic, and surgical treatments have been tried, but none completely effective. The aim present study to evaluate whether a combined treatment sclerotherapy topical therapy with propranolol 0.5% nasal formulation would reduce epistaxis due HHT improve patient's quality life. Methods An observational cross‐sectional was carried out. primary outcome measure...
<h3>Background and importance</h3> Over the past 10 years, a pharmacotherapy revolution in treatment of moderate to severe plaque psoriasis (MS-PP) has occurred. In our country, prescription ustekinumab increased greatly since its approval 2009. Therefore, it is now time reflect on use assess real world setting, before arrival newly approved drugs. <h3>Aim objectives</h3> The primary end point was drug survival for MS-PP treatment. secondary effectiveness <h3>Material methods</h3> A...